Skip to main contentAI and Advanced
/
INDSWFTLAB · NSEBSE SENSEX74,314.59-0.03%BSE |
NIFTY 5023,270.6+0.23%NSE |
NIFTY BANK56,055.75-0.42%NSE |
NIFTY IT29,155.6+0.23%NSE |
NIFTY AUTO27,159.15+0.99%NSE |
NIFTY FMCG45,572.7+0.03%NSE |
NIFTY PHARMA26,579.25+1.66%NSE |
NIFTY 50022,654.65+0.54%NSE |
IN
NSE · Equity shares · Biotechnology & Drugs14.35 · 3.94%
Ind-Swift Laboratories Ltd INDSWFTLAB
NSE:INR 378.25
BSE:INR 378.1
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections8 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for INDSWFTLAB
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 363.9
Day rangeINR 362.45 — INR 386.2
52-week rangeINR 87 — INR 404
Volume5.45 L
Market cap2,033.16
P/ENot available
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)641.29
Net Income (INR Cr)41.42
EPS5.92
Research path: Interpret Ind-Swift Laboratories Ltd's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
INDSWFTLABInd-Swift Laboratories Ltd1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,673.35 | 1,438.34 | 1,165.11 |
| Cash Equivalents | 429.85 | Not available | 0 |
| Other Liabilities Total | 19.8 | 18.86 | 1.23 |
| Long Term Debt | 12.11 | 24.09 | 8.17 |
| Common Stock Total | 86.84 | 68.74 | 59.09 |
| Other Current Assets Total | 158.42 | 400.69 | 394.74 |
| Total Assets | 1,673.35 | 1,438.34 | 1,165.11 |
| Current Portof LT Debt/Capital Leases | 2.6 | 1.49 | 0 |
| Total Equity | 1,384.02 | 1,173 | 931.46 |
| Long Term Investments | 240.56 | 178.45 | 113.33 |
| Retained Earnings(Accumulated Deficit) | 1,297.19 | 609.17 | 567.83 |
| Total Common Shares Outstanding | 8.68 | 6.87 | 5.91 |
| Tangible Book Valueper Share Common Eq | 156.22 | 169.08 | 157.64 |
| Total Liabilities | 289.33 | 265.34 | 233.65 |
| Total Debt | 20.5 | 40.86 | 16.62 |
| Short Term Investments | 42.01 | 53.61 | 0 |
| Cashand Short Term Investments | 471.86 | 78.03 | 36.2 |
| Total Receivables Net | 198.55 | 257.19 | 213.67 |
| Notes Payable/Short Term Debt | 5.59 | 13.43 | 5.46 |
| Accounts Receivable-Trade Net | 198.55 | 167.44 | 170.11 |
| Property/Plant/Equipment Total-Net | 286.52 | 260.07 | 5.36 |
| Minority Interest | -0.06 | -0.03 | -0.02 |
| Total Current Liabilities | 257.29 | 220.58 | 221.28 |
| Total Inventory | 147.93 | 114.18 | 10.46 |
| Accounts Payable | 145.86 | 110.23 | 93.98 |
| Other Currentliabilities Total | 103.23 | 95.43 | 121.84 |
| Total Long Term Debt | 12.3 | 25.94 | 11.16 |
| Intangibles Net | 27.46 | 10.68 | Not available |
| Other Long Term Assets Total | 68.52 | 44.64 | 31.85 |
| Note Receivable-Long Term | 73.54 | 79.15 | 353.43 |
| Total Current Assets | 976.75 | 865.35 | 661.13 |
| Capital Lease Obligations | 0.2 | 1.84 | 3 |
| Accumulated Depreciation Total | Not available | -308.09 | -2.77 |
| Other Equity Total | Not available | 25.6 | -2.77 |
| Prepaid Expenses | Not available | 15.26 | 6.07 |
| Additional Paid-In Capital | Not available | 469.49 | 307.31 |
| Cash | Not available | 24.43 | 36.2 |
| Property/Plant/Equipment Total-Gross | Not available | 568.16 | 8.13 |
| Unrealized Gain(Loss) | Not available | 0 | 0 |
Fundamentals
Valuation and ratios
Valuation
Price to Sale Ratio3.17
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk56.36
Analyst consensus
Analyst consensus unavailable.
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
Peer data unavailable in the company profile payload.
Shareholding
Ownership
- Promoter
- 42.93%
- FII
- 10.70%
- Other
- 46.37%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Ind-Swift Laboratories Ltd Upgraded to Hold on Technical and Financial Improvements - Markets MojoMarket news · 3 Jun 2026, 8:50 pm
Ind-Swift Laboratories Ltd Upgraded to Hold on Technical and Financial Improvements Markets Mojo
Ind-Swift Labs Consolidated March 2026 Net Sales at Rs 169.79 crore, up 22.82% Y-o-Y - Moneycontrol.comMarket news · 3 Jun 2026, 12:44 pm
Ind-Swift Labs Consolidated March 2026 Net Sales at Rs 169.79 crore, up 22.82% Y-o-Y Moneycontrol.com
Ind-Swift Laboratories Ltd is Rated Sell - Markets MojoMarket news · 3 Jun 2026, 2:01 am
Ind-Swift Laboratories Ltd is Rated Sell Markets Mojo
Ind-Swift Laboratories Ltd Sees Bullish Momentum Shift Amid Strong Technical Signals - Markets MojoMarket news · 2 Jun 2026, 2:37 pm
Ind-Swift Laboratories Ltd Sees Bullish Momentum Shift Amid Strong Technical Signals Markets Mojo
Ind-Swift Labs Yearly results, Financial Summary - The Economic TimesMarket news · 2 Jun 2026, 10:51 am
Ind-Swift Labs Yearly results, Financial Summary The Economic Times
Ind-Swift Laboratories Ltd is Rated Sell - Markets MojoMarket news · 1 Jun 2026, 5:25 pm
Ind-Swift Laboratories Ltd is Rated Sell Markets Mojo
Corporate actions
Events
- annual General MeetingEGM
- board MeetingsInter-alia, to consider proposal for raising of funds by way of issuance of one or more instruments including equity shares or any other mode as may be considered.
- board MeetingsAudited Results
- annual General MeetingPOM
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- board MeetingsQuarterly Results
Rusaka Markets Community
Discussion and sentiment for Ind-Swift Laboratories Ltd
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Not available
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- INDSWFTLAB
- BSE Code
- 532305
Questions
Stock FAQ
What is the symbol and ISIN of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd has the symbol INDSWFTLAB and ISIN - INE915B01019.
What is the current price of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd is currently trading at INR 378.25.
What are the year high and year low of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd has a year high of INR 404.00 and a year low of INR 87.00.
What is the market capitalization of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd has a market capitalization of INR 2,033.16 crore.
What is the P/E ratio of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd has a P/E ratio of NA.
What is the dividend yield of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd has a dividend yield of NA.
How is the financial performance of Ind-Swift Laboratories Ltd based on revenue, net income, and EPS?
Ind-Swift Laboratories Ltd has revenue of INR 641.29 crore, net income of INR 41.42 crore, and EPS of NA.
What is the book value of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd has a book value of NA.
What is the debt-to-equity ratio of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Ind-Swift Laboratories Ltd?
Ind-Swift Laboratories Ltd has a price-to-book ratio of NA and a price-to-sales ratio of 3.17.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.